Virus News and Research

Latest Virus News and Research

Regenerating sensory hair cells could help treat hearing loss

Regenerating sensory hair cells, which produce electrical signals in response to vibrations within the inner ear, could form the basis for treating age- or trauma-related hearing loss. One way to do this could be with gene therapy that drives new sensory hair cells to grow.

14 May 2012

FDA ADAC recommends approval of Quad for HIV-1 infection

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.

14 May 2012

HIV community supports rapid OTC testing

Who's Positive, a national HIV awareness organization, today announced the results of a year-long online survey measuring support for over-the counter (OTC) HIV testing. The organization will present these results at the upcoming U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee (BPAC) on May 15, 2012.

11 May 2012

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

Forgive us if we don't cheer at the prospect of adding 32 million to the total number of Americans who are dozens of pounds too heavy, a count that stood in 2010 at 78 million.

11 May 2012

New insights into how body's innate immunity is triggered to create effective immune response

Singapore scientists from Bioprocessing Technology Institute (BTI) under the Agency of Science, Technology and Research (A*STAR) have for the first time, identified the molecular 'switch' that directly triggers the body's first line of defence against pathogens, more accurately known as the body's "innate immunity".

11 May 2012

FDA panel recommends approval of Truvada as preventive treatment for HIV

"In a move that could lead to a new milestone for treatment in the evolution of the worldwide AIDS epidemic," a Food and Drug Administration (FDA) panel on Thursday recommended Gilead Sciences' Truvada as a treatment for preventing HIV infection among healthy people at risk of contracting the virus, Reuters reports, noting, "It already has FDA approval to treat people infected with the human immunodeficiency virus".

11 May 2012

HIV prevention drug receives FDA panel's backing

The drug has already been approved as a treatment for HIV/AIDS. The FDA is expected to decide about approval by June 15.

11 May 2012

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

RNP granules exit the nucleus via new budding mechanism akin to herpes-type viruses

New evidence published in Cell by Vivian Budnik, PhD, Melissa J. Moore, PhD, and colleagues at the University of Massachusetts Medical School, reveals a novel budding mechanism, similar to the process used by some viruses, capable of exporting large ribonucleoprotein particles from the nucleus to the cytoplasm.

11 May 2012

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

"Bacteria, viruses and parasites cause around two million cases of cancer in the world each year, experts believe," the Press Association/Guardian reports. According to the news service, "Scientists carried out a statistical analysis of cancer incidence to calculate that around 16 percent of all cancers diagnosed in 2008 were infection-related," and "the proportion of cancers linked to infection was three times higher in developing countries than in developed ones."

10 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

ArcDia completes € 2.7 million funding round

ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.

9 May 2012

Truvada deemed safe & effective in HIV infection risk reduction

Gilead Sciences Inc's Truvada pills are deemed safe and effective for reducing the risk of HIV infection, U.S. regulators said on Tuesday. But they recommended a cautious approach for using the drug in efforts to prevent the virus that causes AIDS.

9 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

Option for couples to test together, access ART for prevention can reduce HIV risk

"If we don't leverage the power of innovation to transform how health services are provided and utilized, efforts to stop new HIV infections and AIDS-related deaths can reach a stalemate," UNAIDS Executive Director Michel Sidibe writes in this opinion piece in the Huffington Post's "Healthy Living" blog.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Virus News and Research

Latest Virus News and Research

Regenerating sensory hair cells could help treat hearing loss

FDA ADAC recommends approval of Quad for HIV-1 infection

HIV community supports rapid OTC testing

Viewpoints: Two views on how to fight obesity; Tough choices for big business on health costs

New insights into how body's innate immunity is triggered to create effective immune response

FDA panel recommends approval of Truvada as preventive treatment for HIV

HIV prevention drug receives FDA panel's backing

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

RNP granules exit the nucleus via new budding mechanism akin to herpes-type viruses

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Treatable infections responsible for nearly 2M cases of cancer globally each year, study suggests

Researchers use clever screening methods to speed vaccine production

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

Inovio first quarter total revenue decreases to $1.7 million

ArcDia completes € 2.7 million funding round

Truvada deemed safe & effective in HIV infection risk reduction

One in six cancer cases worldwide related to preventable or curable infections

Option for couples to test together, access ART for prevention can reduce HIV risk

BioDiem announces new vaccine research collaboration with French-based VIVALIS

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in